Yelin Lapidot Holdings Management Ltd. Has $5.29 Million Stock Position in InMode Ltd. $INMD

Yelin Lapidot Holdings Management Ltd. lifted its position in shares of InMode Ltd. (NASDAQ:INMD) by 29.9% in the first quarter, HoldingsChannel reports. The fund owned 387,005 shares of the healthcare company’s stock after buying an additional 89,122 shares during the period. InMode accounts for approximately 1.1% of Yelin Lapidot Holdings Management Ltd.’s investment portfolio, making the stock its 24th largest holding. Yelin Lapidot Holdings Management Ltd.’s holdings in InMode were worth $5,294,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Doma Perpetual Capital Management LLC lifted its position in InMode by 26.8% during the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,838,431 shares of the healthcare company’s stock valued at $42,293,000 after purchasing an additional 599,108 shares during the period. Topline Capital Management LLC grew its position in shares of InMode by 2,296.8% during the 3rd quarter. Topline Capital Management LLC now owns 264,770 shares of the healthcare company’s stock worth $3,945,000 after buying an additional 253,723 shares during the period. Ancient Art L.P. acquired a new stake in shares of InMode during the 3rd quarter worth approximately $14,254,000. DGS Capital Management LLC raised its stake in shares of InMode by 127.7% during the fourth quarter. DGS Capital Management LLC now owns 79,613 shares of the healthcare company’s stock worth $1,170,000 after buying an additional 44,654 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of InMode during the fourth quarter worth approximately $624,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Trading Down 0.0%

InMode stock opened at $14.63 on Monday. The firm has a market capitalization of $840.70 million, a P/E ratio of 10.75 and a beta of 1.94. InMode Ltd. has a 1 year low of $12.72 and a 1 year high of $16.74. The business has a 50-day moving average of $13.92 and a 200-day moving average of $14.13.

InMode (NASDAQ:INMD) last announced its quarterly earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.05). InMode had a net margin of 23.27% and a return on equity of 13.47%. The firm had revenue of $82.02 million during the quarter, compared to analyst estimates of $79.84 million. During the same quarter in the prior year, the business earned $0.31 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis.

Wall Street Analysts Forecast Growth

INMD has been the topic of a number of recent research reports. Robert W. Baird reduced their price objective on shares of InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Barclays set a $19.00 target price on shares of InMode and gave the company an “overweight” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.00.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.